Multiple sclerosis (relapsing-remitting) - dimethyl fumarate: evaluation report
01. Pre-Meeting Briefing prepared by NICE
02. Submission from the technology manufacturer Biogen Idec
03. Patient Access Scheme from the Manufacturer
04. NICE request to the manufacturer for clarification on their submission
05. Manufacturer clarification response
06. Consultee submission - The Multiple Sclerosis Society
07. Consultee submission - The Multiple Sclerosis Trust
08. Consultee submission - The Association of British Neurologists
09. Consultee submission - The Royal College of Pathologists
10. Consultee submission - The United Kingdom Clinical Pharmacy Association
11. Patient expert personal perspective from Catherine John
12. Patient expert personal perspective from Nick Rijke
13. Clinical expert personal perspective from Dr Jacqueline Palace
14. Patient expert personal perspective from Professor Neil Robertson
15. Evidence Review Group report prepared by York Centre for Reviews and Dissemination and Centre for Health Economics
16. Errata to the Evidence Review Group report
17. Addendum to the Evidence Review Group report
18. Manufacturer factual accuracy check of Evidence Review Group report
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal.
* Users of Google chrome should click the link below and then click the small PDF icon in the far right of the address bar to successfully access this document *
Multiple sclerosis (relapsing-remitting) - dimethyl fumarate: evaluation report
19 February 2014 (10.51 Mb 14 sec) |
This page was last updated: 30 January 2015